Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and...

Area of Science:

• Nanomedicine and Biomedical Engineering
• Oncology and Cancer Therapeutics
• Molecular Imaging and Diagnostics

Background:

• Prostate cancer (PCa) presents significant challenges in early detection, treatment resistance, and metastasis.
• Current limitations necessitate innovative approaches for effective PCa management.
• Nanomaterials offer a promising platform for integrated diagnostic and therapeutic strategies in PCa.

Purpose of the Study:

• To review recent advancements in nanomaterial platforms for prostate cancer theranostics.
• To analyze the design-function-application-translation framework of nanocarriers for PCa.
• To highlight the potential and challenges of nanomedicine in PCa management.

Main Methods:

• Comprehensive review of major nanomaterial platforms (lipid-based, polymeric, AuNPs, MNPs, biomimetic, smart nanocarriers).
• Focus on applications including imaging enhancement, biosensing, targeted delivery, and multimodal therapies (phototherapy, CDT, immunotherapy).
• Analysis of engineering design principles influencing diagnostic and therapeutic outcomes.

Main Results:

• Nanomaterials enable enhanced imaging, biomarker detection, targeted delivery, and multimodal cancer therapies.
• Engineered multimodal nanocarriers integrate targeting, stimulus-responsive release, and therapy monitoring.
• Prostate-specific membrane antigen (PSMA)-targeted nanoplatforms show promise for theranostic integration.

Conclusions:

• Nanomedicine can improve tumor selectivity, imaging sensitivity, and therapeutic efficacy while reducing toxicity in PCa.
• Clinical translation is hindered by challenges like biodistribution, protein corona, manufacturing, and safety.
• Further research and standardization are crucial for successful clinical integration of nanomedicine in PCa care.